Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20489967 | 0.82 | FDPS (0.33) | CYP4F2CYP4A11ALDH1A1CES2CES1 | |
| SCHEMBL2345689 | 0.78 | CYP4F2 (0.39) | CYP4F2CYP4A11CES2CES1 | |
| SCHEMBL2340944 | 0.78 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1CES2CES1 | |
| SCHEMBL2340906 | 0.76 | CYP4F2 (0.42) | CYP4F2CYP4A11CES2CES1 | |
| SCHEMBL2348421 | 0.74 | EPHX1 (0.46) | CES2 | |
| SCHEMBL2343700 | 0.74 | EPHX1 (0.41) | CYP4F2CYP4A11CES2 | |
| SCHEMBL2350082 | 0.74 | EPHX1 (0.46) | CES2 | |
| SCHEMBL2340575 | 0.74 | CES2 (0.45) | CYP4F2CYP4A11CES2CES1 | |
| SCHEMBL2349262 | 0.74 | CES2 (0.45) | CYP4F2CYP4A11CES2CES1 | |
| SCHEMBL173322 | 0.71 | FFAR3 (0.41) | TDP1FFAR3CYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556096-B2 | Unsymmetric bisphosphite | EVONIK DEGUSSA GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| EP-2906572-B1 | MIXTURES OF CONSTITUTIONAL ISOMERS OF BIPHOSPHITES | EVONIK DEGUSSA GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-9499463-B2 | Mixtures of constitutionally isomeric bisphosphites | EVONIK DEGUSSA GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2906571-B1 | ASYMMETRIC BIPHOSPHITE | EVONIK DEGUSSA GMBH (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-20150290633-A1 | ASYMMETRICAL BISPHOSPHITE | EVONIK DEGUSSA GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150273455-A1 | MIXTURES OF CONSTITUTIONALLY ISOMERIC BISPHOSPHITES | EVONIK DEGUSSA GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| EP-2906571-A1 | ASYMMETRICAL BISPHOSPHITE | Evonik Degussa GmbH (DE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906572-A1 | MIXTURE OF CONSTITUTIONAL ISOMER BISPHOSPHITES | Evonik Degussa GmbH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-9018420-B2 | Use of supported ionic liquid phase (SILP) catalyst systems in the hydroformylation of olefin-containing mixtures to aldehyde mixtures with a high content of aldehydes unbranched in the 2 position | EVONIK OXENO GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| EP-1924357-B1 | CARBONYLATION METHOD BY ADDING SECONDARY STERICALLY HINDERED AMINES | EVONIK DEGUSSA GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-20060100453-A1 | Novel phosoxophite legands and use thereof in carbonylation processes | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 2006-05-11 | — | — | US | disclosed |
| US-20060058557-A1 | Bis-chelating ligand and use thereof in carbonylation processes | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 2006-03-16 | — | — | US | disclosed |
| EP-1485392-B1 | BISPHOSPHITE LIGANDS FOR CARBONYLATION PROCESSES | UNION CARBIDE CHEM PLASTIC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1554293-A1 | BIS-CHELATING LIGAND AND USE THEREOF IN CARBONYLATION PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005063781-A1 | METHOD FOR PRODUCING ORGANOACYLPHOSPHITES | OXENO OLEFINCHEMIE GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063776-A1 | METHOD FOR PRODUCING TRIVALENT ORGANOPHOSPHORUS COMPOUNDS | OXENO OLEFINCHEMIE GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
| EP-1485392-A2 | BISPHOSPHITE LIGANDS FOR CARBONYLATION PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004035595-A1 | BIS-CHELATING LIGAND AND USE THEREOF IN CARBONYLATION PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003078444-A2 | BISPHOSPHITE LIGANDS FOR CARBONYLATION PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2003-09-25 | — | — | WO | disclosed |
| US-4642363-A | Method of preparing trialkyl organo-oxysilanes | DYNAMIT NOBEL AG (DE) | 1987-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100453-A1 | Novel phosoxophite legands and use thereof in carbonylation processes | PGLS, PRDX4, PFAS | TDP1 2853/4885FFAR3 4320/4885CYP4F2 162/4885 |
| US-20150273455-A1 | MIXTURES OF CONSTITUTIONALLY ISOMERIC BISPHOSPHITES | FBP1, PFKFB1, PFKFB2 | TDP1 3651/4885FFAR3 2749/4885CYP4F2 18/4885 |
| US-20150290633-A1 | ASYMMETRICAL BISPHOSPHITE | BPGM, PFKFB1, PFKFB4 | TDP1 2851/4885FFAR3 1639/4885CYP4F2 113/4885 |
| US-20060058557-A1 | Bis-chelating ligand and use thereof in carbonylation processes | CBR1, CBR3, AR | TDP1 4663/4885FFAR3 1318/4885CYP4F2 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.